Radiofrequency Ablation Versus Standard Surgery for the Treatment of Second and Third Degree Haemorrhoids (ORION Trial): A Multicentre Double Blind Randomised Controlled Trial
Background: Radiofrequency ablation (RFA) is a new treatment for haemorrhoidal disease. Proponents suggest it reduces postoperative pain and maintains low recurrence rates, however evidence for clinical effectiveness and cost remains limited.Methods: ORION is a pragmatic, multicentre, patient- and assessor-blinded, parallel-group, randomised non-inferiority trial conducted in 17 acute UK National Health Service hospitals ( ISRCTN14474552). Adults with symptomatic second- or third-degree haemorrhoids who had failed conservative management were randomised to RFA or standard care (SC). SC comprised procedures recommended by European guidelines (haemorrhoidal artery ligation, haemorrhoidectomy, stapled haemorrhoidopexy), selected according to surgeon preference. Following patient consultation, postoperative pain (superiority) and recurrence (non-inferiority margin<10%) were selected as co-primary outcomes. The primary analyses were modified intention to treat.Findings: Between 7th January 2022 and 8th January 2024, 383 participants (mean age 48·6 years, 61% male) were randomised. 179 patients underwent RFA, 152 received SC (131 haemorrhoidal artery ligation, 20 haemorrhoidectomy, one stapled haemorrhoidopexy), and 52 received no procedure. At postoperative day 7, the adjusted mean difference in self-reported pain between RFA and SC was 0·17 (95% CI -0·67, 1·01). Twelve-month recurrence was 47% after RFA versus 39% after SC (adjusted absolute difference 7·4%,95% CI -5·3% to 20·1%). Neither superiority for pain nor non-inferiority for recurrence was demonstrated. Secondary outcomes (adverse events, symptom severity, incontinence, complications) were comparable. RFA reduced healthcare costs because of shorter operating times (adjusted mean difference 9·1 minutes, 95% CI 7·6, 10·7) and lower consumable costs but patients reported more time off work (mean difference 2·61 days, 95% CI 0·33-4·89). Interpretation: These findings do not support the routine adoption of RFA on the basis of improved patient-centred outcomes and highlight the importance of evaluating new surgical technologies before widespread implementation.